azole resistance – Page 5

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, especially in patients whose immune systems are weakened. The researchers found that while most hospitals have good access to testing and antifungal medications, some important tests are still missing, and many hospitals send samples to other facilities for testing, which can delay treatment. Since this region has unusually high rates of fungal infections that resist common antifungal drugs, improving access to advanced diagnostic tests is crucial for patient survival.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection of his heart valve after surgery. The infection was caused by a resistant yeast that didn’t respond to initial antifungal treatment. Doctors used molecular testing to identify the exact fungal species and tested how it responded to different medications. After switching to a different antifungal drug called caspofungin, the patient recovered completely and remained healthy.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against dangerous fungal infections caused by Aspergillus species. The drug works by removing essential zinc that the fungus needs to survive. The study found that nitroxoline was highly effective against all tested fungal strains, including those resistant to modern antifungal drugs, suggesting it could be a promising alternative treatment for serious fungal infections.

Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes

mycolabadmin

This study found that different azole antifungal drugs work better against different versions of an enzyme (Cyp51) that fungi need to survive. By combining two azole drugs that each target different enzyme versions, researchers achieved stronger antifungal effects than either drug alone. This discovery suggests a new strategy for treating stubborn fungal infections by carefully selecting drug combinations based on which enzyme versions the fungus possesses.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection of his heart valve after receiving an artificial valve replacement. The initial antibiotic (itraconazole) did not work because the fungus became resistant, likely by forming a protective biofilm. After identifying the resistant fungus through specialized testing, doctors switched to a different medication called caspofungin. The patient fully recovered with this new treatment and remained healthy during follow-up, showing that combination of precise identification and targeted treatment can overcome antibiotic resistance.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against Aspergillus fungi that cause serious infections in immunocompromised patients. The drug works by removing zinc that the fungus needs to survive. The study found that nitroxoline was very effective against all tested fungal strains, including those resistant to modern antifungal drugs, suggesting it could potentially be repurposed as a new treatment option.

Evaluation of Antifungal Activity Against Candida albicans Isolates From HIV-Positive Patients with Oral Candidiasis in a Major Referral Hospital, West Java, Indonesia

mycolabadmin

This study examined fungal infections in HIV-positive patients’ mouths at an Indonesian hospital. Researchers identified which Candida species caused the infections and tested how well common antifungal medications worked against them. They found that while a specific antifungal drug (fluconazole) was effective in most cases, some infections showed resistance, suggesting the need for careful monitoring and personalized treatment approaches.

Insights into the structure, function, and impact of Candida albicans UPC2 gene on azole resistance; a mini-review

mycolabadmin

Candida albicans is a common fungal infection that doctors treat with azole medications, but the fungus is increasingly developing resistance to these drugs. Scientists have discovered that a gene called UPC2 plays a key role in this resistance by controlling the production of enzymes that help the fungus survive azole treatment. Understanding how UPC2 works could help develop new strategies to overcome drug-resistant fungal infections.

Research Keyword: azole resistance